Climb Bio (CLYM) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio (CLYM) has outperformed ProKidney (PROK) over the past year, gaining 549.1% versus a loss of 47.0%. Over five years, CLYM leads with a -33.6% price change compared with -84.1% for PROK. ProKidney is the larger company by market cap ($656.7 million vs $618.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | PROK |
|---|---|---|
| Share price | $10.78 | $1.65 |
| Market cap | $618.88M | $656.66M |
| 1-day change | +0.61% | +4.78% |
| YTD return | +167.75% | -29.91% |
| 1-year return | +549.09% | -46.96% |
| 5-year return | -33.64% | -84.09% |
| EPS (TTM) | $-0.82 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $3.48 |
| 52-week low | $1.64 | $1.30 |
| Distance from 52-week high | -41.22% | -52.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +155.87% | +279.94% |
| Average volume | 1.38M | 1.30M |
| Shares outstanding | 57.44M | 208.93M |
| Employees | 28 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed PROK by 596.1 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
CLYM vs PROK FAQ
Which is bigger, Climb Bio or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $656.66M compared with $618.88M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or PROK?
CLYM returned +549.09% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and ProKidney in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Climb Bio and Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney.